Novel selective calpain 1 inhibitors as potential therapeutics in Alzheimer’s disease

Manuscript Number: 

15-0618R1

Author(s): 
Ottavio Arancio, Mauro Fa, Jenny Libien, Vladislav A. Litosh, Pavel A. Petukhov, Faisal Saeed, Isaac I. Schiefer, Li W. Shen, Marton I. Siklos, Agnieszka Staniszewski, Subhasish Tapadar, Andrew F. Teich, Gregory R.J. Thatcher, Hong Zhang

Disclosures

Ottavio Arancio

  • Patents/Royalties
    A patent has been filed and licensed for commercialization.

Mauro Fa

  • Patents/Royalties
    I am one of the inventors in the patent #PCT/US2013/024364 "NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF", covering also the molecules described in this article. Compounds have been licensed by Columbia University. I did not receive any royalty. I did not work and I am not working for any of the commercial licensees.

Jenny Libien

  • Equity:
    No stock options. Total stock ownership is approx. $175,000. Multiple publicly traded companies including facebook, amazon, Microsoft, coca cola ,PepsiCo, Berkshire Hathaway. There are a few biomedical or pharmaceutical ownership Biogen - 75 shares, Johnson and Johnson 76 shares, Merck 150 shares, Proctor and Gamble 53 shares.
    Grants
    • Agency: 
      NIH-STTR R41 NS067964 (S. Mangla, Downstate PI, Hybernia Medical LLC)
      Dates: 
      0.5 calendar months in 2014 (9/1/11-8/1/14)

Vladislav A. Litosh

  • Nothing to Disclose

Pavel A. Petukhov

  • Nothing to Disclose

Faisal Saeed

  • Nothing to Disclose

Isaac I. Schiefer

  • Nothing to Disclose

Li W. Shen

  • Nothing to Disclose

Marton I. Siklos

  • Nothing to Disclose

Agnieszka Staniszewski

  • Nothing to Disclose

Subhasish Tapadar

  • Nothing to Disclose

Andrew F. Teich

  • Nothing to Disclose

Gregory R.J. Thatcher

  • Patents/Royalties
    Inventor on patents associated with calpain inhibitors used in this study

Hong Zhang

  • Nothing to Disclose